Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 09 Apr 2022
PBS listing of Paxlovid (nirmatrelvir and ritonavir)
9 April 2022 - Commencing 1 May 2022, Paxlovid (nirmatrelvir and ritonavir) will be listed on the PBS as a General ...
Posted by Michael Wonder on 09 Apr 2022
Upadacitinib, abrocitinib and tralokinumab for atopic dermatitis
8 April 2022 - A rare multiple technology assessment from NICE. ...
Posted by Michael Wonder on 09 Apr 2022
Life Saving Drugs Program – medicines reviews recommendations
7 April 2022 - This document outlines 51 recommendations from the Life Saving Drugs Expert Panel review. ...
Posted by Michael Wonder on 09 Apr 2022
Joint statement from CMS Administrator Chiquita Brooks-LaSure and FDA Commissioner Robert M. Califf on ensuring access to safe and effective treatments
8 April 2022 - Ensuring the availability of innovative interventions for people is a shared priority for both the CMS and ...
Posted by Michael Wonder on 09 Apr 2022
PBAC recommendation for nirmatrelvir and ritonavir (Paxlovid) - March 2022
9 April 2022 - The PBAC undertook an expedited consideration of a submission to add the combination product, nirmatrelvir and ritonavir ...
Posted by Michael Wonder on 08 Apr 2022
NICE recommends Koselugo for the treatment of neurofibromatosis type 1
8 April 2022 - NICE has recommended AstraZeneca and MSD’s Koselugo (selumetinib) for use by the NHS in England, within ...
Posted by Michael Wonder on 08 Apr 2022
Eisai statement on the Centers for Medicare and Medicaid Services’ National coverage determination with coverage with evidence development for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease
8 April 2022 - Eisai stands with people living with Alzheimer’s disease and their families, health care professionals and other ...
Posted by Michael Wonder on 08 Apr 2022
TGA approved Yuflyma
8 April 2022 - The TGA has approved yet another adalimumab biosimilar. ...
Posted by Michael Wonder on 08 Apr 2022
TGA provisionally approves Pfizer’s COVID-19 vaccine (Comirnaty), for use as a booster for individual aged 12–15 years old
8 April 2022 - The TGA has provisionally approved the Pfizer Australia Pty Ltd COVID-19 vaccine, Comirnaty, for use as a ...
Posted by Michael Wonder on 07 Apr 2022
What is the solution to America’s deepening access to medicines crisis?
7 April 2022 - Last week, a bill to limit the cost of insulin in the US passed the House of ...
Posted by Michael Wonder on 07 Apr 2022
CMS finalises Medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease
7 April 2022 - Today, the CMS released a national policy for coverage of aducanumab (Aduhelm) and any future monoclonal antibodies ...
Posted by Michael Wonder on 07 Apr 2022
CADTH launches consultations on proposals to enhance drug review processes
4 April 2022 - CADTH has launched consultations on a proposed process for non-sponsored reimbursement reviews and a streamlined process ...
Posted by Michael Wonder on 07 Apr 2022
Clayton Pharmaceuticals and VistaPharm receive FDA approval for sucralfate oral suspension
7 April 2022 - Approval validates the use of novel pathway for bioequivalence of complex generic drug products, which increases ...
Posted by Michael Wonder on 07 Apr 2022
Concerns two different flu vaccines create two tier system for 65 and overs
8 April 2022 - PHARMAC is being accused of kicking an own goal on flu jabs, after those aged 65 ...
Posted by Michael Wonder on 07 Apr 2022
BeiGene’s Brukinsa quickly passes HIRA’s reimbursement review
7 April 2022 - BeiGene’s Brukinsa (zanubrutinib), a next-generation BTK inhibitor, passed the Health Insurance Review and Assessment Service’s Cancer ...